Comparative Pharmacology
Head-to-head clinical analysis: ESIMIL versus VIZZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESIMIL versus VIZZ.
ESIMIL vs VIZZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
80 mg orally once daily
None Documented
None Documented
2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases).
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
Primarily renal (>90% as unchanged drug); biliary/fecal <10%.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Category C
Category C
Unknown
Unknown